Payer+Provider's Health System Review
July 24, 2020
Moderna’s stock price has continued to climb to record highs on the premise that their novel mRNA-based vaccine technology can take control of the spread of COVID-19. Since the beginning of January 2020 to the time of the writing of this article,…